サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771079

エリスロポエチン刺激剤市場- 世界の産業規模、シェア、動向、機会、予測：タイプ別、用途別、地域別セグメント、競合、2020年～2030年

Erythropoietin Stimulating Agents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 182 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

エリスロポエチン刺激剤市場- 世界の産業規模、シェア、動向、機会、予測：タイプ別、用途別、地域別セグメント、競合、2020年～2030年
出版日: 2025年07月14日
発行: TechSci Research
ページ情報: 英文 182 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

エリスロポエチン刺激剤の世界市場は2024年に74億5,000万米ドルとなり、2030年までCAGR 8.14％で成長すると予測されています。

エリスロポエチン刺激剤（ESA）はエリスロポエチンの合成製剤で、腎臓で自然に産生される糖タンパク質ホルモンであり、骨髄での赤血球産生を調節します。これらの薬剤は、慢性腎臓病（CKD）、がん治療、HIV/AIDS、赤血球数が少ない外科手術に伴う貧血の治療に広く使用されています。貧血の世界の有病率の増加、特に妊娠中の女性、小児、慢性疾患を持つ人々などの脆弱な集団における貧血の増加が、ESA療法の需要を牽引しています。WHO2025によると、貧血は依然として世界的に重要な健康問題であり、低所得層や農村部の人々に不釣り合いな影響を及ぼしています。さらに、世界人口の高齢化は貧血につながりやすい状況にあり、ESAの持続的な使用拡大に寄与すると予想されています。ESAは患者のQOL向上に重要な役割を果たしており、貧血に伴う慢性・急性疾患の管理に不可欠な要素となっています。

市場概要
予測期間 2026-2030
市場規模：2024年 74億5,000万米ドル
市場規模：2030年 118億2,000万米ドル
CAGR：2025年～2030年 8.14%
急成長セグメント エポエチンアルファ
最大市場 北米

市場促進要因

腫瘍学の進歩

主な市場課題

特許失効

主要市場動向

エポエチン・バイオシミラーへのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界市場におけるCOVID-19の影響

第5章 顧客の声

第6章 世界のエリスロポエチン刺激剤市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • タイプ別（エポエチンアルファ、エポエチンベータ、ダルベポエチンアルファ、その他）
    • 用途別（がん、腎疾患、抗レトロウイルス治療、神経疾患、その他の用途）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第7章 アジア太平洋地域のエリスロポエチン刺激剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • オーストラリア
    • 日本
    • 韓国

第8章 欧州のエリスロポエチン刺激剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • スペイン
    • イタリア
    • 英国

第9章 北米のエリスロポエチン刺激剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第10章 南米のエリスロポエチン刺激剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのエリスロポエチン刺激剤市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第14章 世界のエリスロポエチン刺激剤市場：SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 PESTEL分析

第17章 競合情勢

  • Amgen Inc.
  • Biocon Limited
  • Celltrion Inc.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Thermo Fisher Scientific
  • LG Lifesciences, Ltd
  • Novartis AG（Sandoz）
  • Panacea Biotec Ltd

第18章 戦略的提言

第19章 調査会社について・免責事項

目次
Product Code: 16145

The Global Erythropoietin Stimulating Agents Market was valued at USD 7.45 billion in 2024 and is projected to grow at a CAGR of 8.14% through 2030. Erythropoietin Stimulating Agents (ESAs) are synthetic forms of erythropoietin, a glycoprotein hormone naturally produced by the kidneys that regulates red blood cell production in the bone marrow. These agents are widely used to treat anemia associated with chronic kidney disease (CKD), cancer therapies, HIV/AIDS, and surgical procedures where red blood cell counts are low. The increasing global prevalence of anemia, especially in vulnerable populations such as pregnant women, children, and individuals with chronic illnesses, is driving demand for ESA therapies. According to WHO 2025, anemia remains a significant global health issue, disproportionately affecting low-income and rural populations. Furthermore, the aging global population, which is more susceptible to conditions leading to anemia, is expected to contribute to sustained growth in ESA usage. ESAs play a crucial role in improving patient quality of life, making them a vital component in managing chronic and acute medical conditions associated with anemia.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.45 Billion
Market Size 2030USD 11.82 Billion
CAGR 2025-20308.14%
Fastest Growing SegmentEpoetin Alfa
Largest MarketNorth America

Key Market Drivers

Advancements in Oncology

The rising incidence of chemotherapy-induced anemia (CIA) has led to a growing reliance on ESAs such as Epoetin Alfa and Darbepoetin Alfa to mitigate fatigue and enhance patient well-being during cancer treatment. Recent advancements in oncology have introduced more effective and targeted therapies, which may reduce the severity of anemia but also require precise supportive treatments like ESAs. Oncology research has also improved the understanding of ESA safety profiles, enabling better identification of patient subgroups that can safely benefit from these therapies. Personalized medicine and oncogenomics have further contributed to tailored ESA administration based on genetic markers and cancer types, optimizing outcomes while minimizing adverse effects. These developments have bolstered ESA integration into oncology protocols, enhancing their clinical utility and market demand.

Key Market Challenges

Patent Expirations

Patent expirations pose a significant challenge to the growth and profitability of the ESA market. As patents for key ESA drugs expire, it paves the way for the introduction of generic and biosimilar versions, intensifying market competition and driving down prices. These lower-cost alternatives often capture a substantial market share, particularly in price-sensitive healthcare systems. While this may improve patient access, it also leads to revenue declines for original ESA manufacturers. The market may become fragmented, with multiple players offering comparable products, increasing pricing pressures and reducing the incentive for continued innovation. Manufacturers are compelled to revise their pricing and market strategies to remain competitive. Although cost savings benefit healthcare systems, the shift can create challenges in ensuring consistent quality, safety, and patient trust in biosimilar products.

Key Market Trends

Shift Toward Epoetin Biosimilars

The emergence and growing acceptance of Epoetin biosimilars are significantly transforming the ESA market landscape. Biosimilars, developed to be highly similar to already approved biologics, offer equivalent safety and efficacy at a lower cost. This price advantage makes biosimilars appealing to healthcare systems and providers aiming to reduce expenditure without compromising treatment quality. The availability of Epoetin biosimilars has increased competition, expanded patient access, and driven broader adoption of ESA therapies, especially in budget-constrained regions. Regulatory approvals from agencies like the FDA and EMA have reinforced confidence in biosimilars, encouraging uptake among physicians and patients. As real-world evidence continues to support their reliability, the shift toward biosimilars is expected to further strengthen, offering substantial cost savings while maintaining treatment standards in managing anemia.

Report Scope:

In this report, the Global Erythropoietin Stimulating Agents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Erythropoietin Stimulating Agents Market, By Type:

  • Epoetin Alfa
  • Epoetin Beta
  • Darbepoetin Alfa
  • Other Types

Erythropoietin Stimulating Agents Market, By Application:

  • Cancer
  • Renal Disorders
  • Anti-retroviral Treatment
  • Neural Diseases
  • Other Applications

Erythropoietin Stimulating Agents Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Erythropoietin Stimulating Agents Market.

Available Customizations:

Global Erythropoietin Stimulating Agents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Feed Phytogenic Market

5. Voice of Customer

6. Global Erythropoietin Stimulating Agents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, And Other Types)
    • 6.2.2. By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Other Applications)
    • 6.2.3. By Region
    • 6.2.4. By Company (2024)
  • 6.3. Market Map

7. Asia Pacific Erythropoietin Stimulating Agents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Erythropoietin Stimulating Agents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. India Erythropoietin Stimulating Agents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. Australia Erythropoietin Stimulating Agents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Japan Erythropoietin Stimulating Agents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. South Korea Erythropoietin Stimulating Agents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Europe Erythropoietin Stimulating Agents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Erythropoietin Stimulating Agents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. Germany Erythropoietin Stimulating Agents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Spain Erythropoietin Stimulating Agents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. Italy Erythropoietin Stimulating Agents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. United Kingdom Erythropoietin Stimulating Agents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. North America Erythropoietin Stimulating Agents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Erythropoietin Stimulating Agents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. Mexico Erythropoietin Stimulating Agents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. Canada Erythropoietin Stimulating Agents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Erythropoietin Stimulating Agents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Erythropoietin Stimulating Agents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Argentina Erythropoietin Stimulating Agents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Colombia Erythropoietin Stimulating Agents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Middle East and Africa Erythropoietin Stimulating Agents Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type
    • 11.2.2. By Application
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Erythropoietin Stimulating Agents Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
    • 11.3.2. Saudi Arabia Erythropoietin Stimulating Agents Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
    • 11.3.3. UAE Erythropoietin Stimulating Agents Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Erythropoietin Stimulating Agents Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. Amgen Inc.
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (In case of listed companies)
    • 17.1.5. Recent Developments
    • 17.1.6. SWOT Analysis
  • 17.2. Biocon Limited
  • 17.3. Celltrion Inc.
  • 17.4. F. Hoffmann-La Roche Ltd
  • 17.5. Intas Pharmaceuticals Ltd
  • 17.6. Johnson and Johnson
  • 17.7. Pfizer Inc.
  • 17.8. Teva Pharmaceutical Industries Ltd
  • 17.9. Thermo Fisher Scientific
  • 17.10. LG Lifesciences, Ltd
  • 17.11. Novartis AG(Sandoz)
  • 17.12. Panacea Biotec Ltd

18. Strategic Recommendations

19. About Us & Disclaimer